A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells

Cell Death and Disease

Volumn 3, Issue 1, 2012, Pages

  Huang, E Y ^a,b   Chen, Y F ^c   Chen, Y M ^a,b   Lin, I H ^a,b   Wang, C C ^a,b   Su, W H ^b   Chuang, P C ^b   Yang, K D ^b,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervical cancer; Galectin 1; H Ras; Radioresistance; Radiosensitivity

Indexed keywords

GALECTIN 1; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; DNA; H2AFX PROTEIN, HUMAN; HISTONE; RAS PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL DEATH; CELL SURVIVAL; CLONOGENESIS; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; GENE OVEREXPRESSION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; IRRADIATION; ONCOGENE H RAS; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; DNA REPAIR; GAMMA RADIATION; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHOSPHORYLATION; RADIATION DOSE; RADIATION EXPOSURE; REPORTER GENE;

COMET ASSAY; DNA; DNA REPAIR; GALECTIN 1; GAMMA RAYS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENES, REPORTER; HELA CELLS; HISTONES; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; RADIATION TOLERANCE; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84863138173     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.120     Document Type: Article

References (39)

1. Huang EY, Wang CJ, Chen HC, Fang FM, Huang YJ, Wang CY et al. Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IVA squamous cell carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 2008; 72: 834-842.
2. Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011; 283: 109-113.
3. Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009; 113: 16-20.
4. Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108: 42-46.
5. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J et al. A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 2007; 67: 104-109. (Pubitemid 44959486)
6. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys 2007; 69: 111-117. (Pubitemid 47247506)
7. Herrera FG, Chan P, Doll C, Milosevic M, Oza A, Syed A et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007; 67: 97-103. (Pubitemid 44959495)
8. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008; 9: 593-601. (Pubitemid 351712630)
9. Le QT, Shi G, Cao H, Nelson DW,Wang Y, Chen EY et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005; 23: 8932-8941. (Pubitemid 46211478)
10. Le QT, Kong C, Lavori PW, O'byrne K, Erler JT, Huang X et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007; 69: 167-175. (Pubitemid 47247510)
11. Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC et al. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 2008; 44: 325-334.
12. Saussez S, Decaestecker C, Lorfevre F, Cucu DR, Mortuaire G, Chevalier D et al. High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas. Int J Oncol 2007; 30: 1109-1117.
13. van den Brûle FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001; 193: 80-87. (Pubitemid 32051116)
14. Parliament MB, Murray D. Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. Semin Radiat Oncol 2010; 20: 232-240.
15. Iliakis G, Metzger L, Muschel RJ, McKenna WG. Induction and repair of DNA double strand breaks in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. Cancer Res 1990; 50: 6575-6579. (Pubitemid 20348782)
16. Cho HJ, Jeong HG, Lee JS, Woo ER, Hyun JW, Chung MH et al. Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J Biol Chem 2002; 277: 19358-19666.
17. Chang IY, Youn CK, Kim HB, Kim MH, Cho HJ, Yoon Y et al. Oncogenic H-Ras upregulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells. Cancer Res 2005; 65: 6811-6819. (Pubitemid 41060719)
18. Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH et al. Oncogenic H-Ras upregulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004; 64: 4849-4857.
19. Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 1988; 239: 645-647. (Pubitemid 18066229)
20. Hermens AF, Bentvelzen PA. Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res 1992; 52: 3073-3082.
21. Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 2007; 9: 341-348. (Pubitemid 46608301)
22. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20: 7486-7493. (Pubitemid 33086908)
23. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002; 277: 37169-37175.
24. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-4515. (Pubitemid 26330463)
25. Rofstad EK, Sundfør K, Lyng H, Tropé CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83: 354-359. (Pubitemid 30453576)
26. Zhao XY, Chen TT, Xia L, Guo M, Xu Y, Yue F et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis 2010; 31: 1367-1375.
27. Kohrenhagen N, Volker HU, Kapp M, Dietl J, Kammerer U. Increased expression of galectin-1 during the progression of cervical neoplasia. Int J Gynecol Cancer 2006; 16: 2018-2022. (Pubitemid 44924365)
28. Rotblat B, Belanis L, Liang H, Haklai R, Elad-Zefadia G, Hancock JF et al. H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 2010; 5: e11991.
29. Satelli A, Rao US. Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett 2011; 301: 38-46.
30. Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogenactivated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 2002; 62: 4142-4150. (Pubitemid 34791086)
31. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A et al. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 1989; 243: 1354-1356. (Pubitemid 19085371)
32. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003; 22: 5866-5875. (Pubitemid 37176707)
33. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 2007; 67: 1046-1053.
34. Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997; 17: 5588-5597. (Pubitemid 27357655)
35. Dodson H, Wheatley SP, Morrison CG. Involvement of centrosome amplification in radiation-induced mitotic catastrophe. Cell Cycle 2007; 6: 364-370.
36. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, André S et al. Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem 2005; 280: 37266-37277. (Pubitemid 41587811)
37. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005; 115: 312-319. (Pubitemid 40586743)
38. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006; 103: 15975-15980. (Pubitemid 44657577)
39. Pilch J, Franzin CM, Knowles LM, Ferrer FJ, Marassi FM, Ruoslahti E. The anti-angiogenic peptide anginex disrupts the cell membrane. J Mol Biol 2006; 356: 876-885. (Pubitemid 43145943)